Compare CRNX & ANDG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | ANDG |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | 52300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | ANDG |
|---|---|---|
| Price | $42.21 | $36.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $76.75 | $31.17 |
| AVG Volume (30 Days) | ★ 1.3M | 376.9K |
| Earning Date | 05-07-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $16.02 |
| Revenue Next Year | $184.67 | $13.67 |
| P/E Ratio | ★ N/A | $44.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $18.12 |
| 52 Week High | $57.99 | $40.23 |
| Indicator | CRNX | ANDG |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 48.29 |
| Support Level | $38.68 | $34.05 |
| Resistance Level | $44.89 | $36.54 |
| Average True Range (ATR) | 1.71 | 2.28 |
| MACD | 0.74 | -0.14 |
| Stochastic Oscillator | 97.89 | 37.96 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.